On a generally forgettable Wednesday for the stock market, with many titles dropping in value, Celcuity (NASDAQ: CELC) stood out by posting a gain. Investors bought into the company, which is moving from the clinical to the commercial stage with the launch of its first regulator-approved product. Celcuity’s stock closed 2.8% higher, on a day when the S&P 500 index slid by 0.3%.
The inaugural commercial launch
Celcuity, a biotech focused on cancer treatments, announced that its Revtorpyk is now commercially available for eligible patients in the U.S. The drug received Food and Drug Administration (FDA) approval in July for certain forms of breast cancer.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
The company added that it has also launched Revtorpyk Support Services, a program that provides financial support and other services to both physicians and patients.
Celcuity said that breast cancer is the second most common cancer, with over two million cases diagnosed around the world in 2022. HR+/HER2 breast cancer, the type Revtorpyk is indicated for, comprises roughly 70% of all instances of the disease.
The market will decide
Since this affliction is so widespread, any weapon in the fight against it is sure to be put to good use.
Celcuity’s first commercialized drug should be a success, so it’s little wonder investors were eager to buy its equity on Wednesday (although the launch was largely priced into the stock). Now it’ll be crucial for investors to monitor how well Revtorpyk does in the market.
Should you buy stock in Celcuity right now?
Before you buy stock in Celcuity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Celcuity wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $379,123!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,396,103!*
That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.
